Abbott has informed employees at its vascular manufacturing operations in Clonmel that it is seeking approximately 200 redundancies from its permanent work force.
The company is seeking to achieve the redundancies on a voluntary basis and is now entering into a 30-day consultation period with its employees. In addition, a few dozen contractor positions will not be renewed when their contracts expire at the end of March.
The proposed redundancies are part of adjustments we are making to meet the evolving needs of the business and to remain competitive in a challenging global environment.
Abbott’s vascular facility in Clonmel currently employs more than 1,400 people, and the facility remains strategically important to Abbott’s global vascular manufacturing network.
Going forward, the Clonmel site will focus primarily on the manufacture of newer, advanced medical devices that incorporate a drug and device combination, such as Absorb™, the world’s first coronary drug eluting bioresorbable vascular scaffold, developed by Abbott for the treatment of coronary artery disease. Capital investment will be made at the site this year to enable it to manufacture these innovative medical technologies. We regret the impact of this adjustment on our employees in Clonmel and the wider community, and our focus is on supporting our impacted employees. Favourable redundancy terms and outplacement services will be provided to affected employees.
Abbott’s vascular facility in Clonmel manufactures a range of vascular devices for global markets. These devices are used in the treatment of vessel diseases of the heart and peripheral blood vessels.
Abbott is one of Ireland’s largest health care companies, employing more than 3,200 people in 11 locations across Ireland. No other site in Ireland is impacted by today’s announcement.